First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac
Publication date
2022-06
Authors
On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
No license information available
Abstract
The treatment of oligometastatic disease using MR guidance is an evolving field. Since August 2018 patients are treated on a 1.5 Tesla MR-Linac (MRL). We present current workflows and practice standards from seven institutions for the initial patients treated for lymph node and liver metastases.
Keywords
(3–6): oligometastases, MOMENTUM, MR-guided radiotherapy, MR-Linac, SABR, Care Planning, Oncology(nursing), Health Policy, Radiology Nuclear Medicine and imaging, Journal Article
Citation
On Behalf of the tumor site group for oligometastatic disease of the Elekta MR-Linac Consortium 2022, 'First multicentre experience of SABR for lymph node and liver oligometastatic disease on the unity MR-Linac', Technical Innovations and Patient Support in Radiation Oncology, vol. 22, pp. 50-54. https://doi.org/10.1016/j.tipsro.2022.04.005